Zoetis stock had its Relative Strength (RS) Rating upgraded from 69 to 74 Wednesday -- a welcome improvement, but still shy of the 80 or better score you prefer to see.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
IBD's unique rating identifies price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the best-performing stocks tend to have an RS Rating north of 80 in the early stages of their moves. See if Zoetis stock can continue to rebound and hit that benchmark.
Looking For Winning Stocks? Try This Simple Routine
Is Zoetis Stock A Buy?
Zoetis stock is within a buying range after climbing above a 187.82 entry in a cup without handle. Once a stock moves 5% or higher beyond the initial entry, it's considered extended and out of buy range. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The drug maker showed -1% EPS growth in its most recent report, while sales growth came in at 1%. Keep an eye out for the company's next round of numbers on or around Aug. 8.
Zoetis stock earns the No. 3 rank among its peers in the Medical-Ethical Drugs industry group. Novartis ADR and Zoetis are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
